Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
POWER: Neoadjuvant Treatment in Resectable Pancreatic Adenocarcinoma
NCT07808567Phase 2Not yet recruiting
- Sponsor
- Gustave Roussy
- Start
- Jan 2027
- Primary completion
- Jan 2029
- Countries
- 1
01
Overview
A Phase 2 trial of FOLFIRINOX, gemcitabine, paclitaxel in pancreatic adenocarcinoma (PDAC), sponsored by Gustave Roussy. Planned start Jan 2027; status: not yet recruiting.
02
Drugs
FOLFIRINOXgemcitabinepaclitaxel
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on NCT07808567.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07808567.